Disorders of Gut-brain InteractioniACTforDGBINCT07814196
Efficacy, and Cost-effectiveness of an Online ACT Intervention for Disorders of Gut-Brain Interaction (iACTforDGBI)
A study testing iACTforDGBI intervention and DGBI School in people with Disorders of Gut-brain Interaction and Distress, Psychological, run by Örebro University, Sweden at 1 site in Sweden.
Trial summary
Test of efficacy and cost-effectiveness of the iACTforDGBI intervention vs an active control group (DGBI School) Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Disorders of Gut-brain Interaction, Distress, Psychological
- What is being tested?
- iACTforDGBI intervention and DGBI School
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 1 siteSweden
- Study dates
- 15 Sep 2026to 30 Sep 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age between 18 and 75 years
- Meeting clinical symptom levels for least one DGBI diagnosis (assessed with the Rome IV Diagnostic Questionnaire for Functional Gastrointestinal Disorders in Adults (Palsson et al., 2016))
- Stable medication for psychiatric symptoms including anxiety, depression and sleep problems for at least two months prior to intervention.
- Ability to read and write Swedish
- Have access to a device (like computer, tablet or smartphone with) with access to the internet and that can be used to attend video conferences and preview the intervention platform (i.e., have a microphone and speakers or headphones).
Who cannot join
- Currently undergoing any form of psychological intervention.
- Increased risk of suicide (≥4 points on MADRS item 9).
- Ongoing or previously diagnosed severe psychiatric disorder, such as schizophrenia spectrum disorders or bipolar disorder.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Sweden1 site, 1 recruiting
- Recruiting
Örebro University
Örebro, SE-701 82
Ines Trindade, +46 19 30 30 00, ines.trindade@oru.se
About this study
Test of efficacy and cost-effectiveness of the iACTforDGBI intervention vs an active control group (DGBI School)
- Being tested
- iACTforDGBI intervention, DGBI School
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
iACTforDGBI interventionBehavioural
Online ACT, mindfulness, and compassion-based intervention, 8 sessions
DGBI SchoolOther
Education on DGBI, diet, and psychological factors
| Study group | Role | What they receive |
|---|---|---|
| iACTforDGBI intervention | Experimental | ACT, mindfulness, and compassion-based online intervention Receives: Behavioral: iACTforDGBI intervention |
| DGBI School | Active comparator | Education on DGBI Receives: Other: DGBI School |
What is being measured
The primary outcome is the main question the study is designed to answer.
Depressive symptoms (Patient Health Questionnaire-9, PHQ-9)
Depressive symptoms measured with the Patient Health Questionnaire-9 (PHQ-9), a 9-item self-report scale. Each item is rated from 0 (not at all) to 3 (nearly every day) and items are summed. Total score ranges from 0 to 27. Higher scores indicate more severe depressive symptoms (worse outcome).
Measured: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up
Gastrointestinal symptoms (Gastrointestinal Symptom Rating Scale, GSRS)
Gastrointestinal symptom severity measured with the Gastrointestinal Symptom Rating Scale (GSRS), a 15-item self-report scale. Each item is rated on a 7-point Likert scale from 1 (no discomfort) to 7 (very severe discomfort), and items are summed. Total score ranges from 15 to 105. Higher scores indicate more severe gastrointestinal symptoms (worse outcome).
Measured: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up
Anxiety symptoms (Generalized Anxiety Disorder 7-item scale, GAD-7)
Anxiety symptoms measured with the Generalized Anxiety Disorder 7-item scale (GAD-7). Each of the 7 items is rated from 0 (not at all) to 3 (nearly every day) and items are summed. Total score ranges from 0 to 21. Higher scores indicate more severe anxiety symptoms (worse outcome).
Measured: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up
Secondary outcomes (11)
Health-related quality of life (EuroQol 5-Dimension 5-Level, EQ-5D-5L)
Health-related quality of life measured with the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L). Five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each with five severity levels, are converted into a single index value using the [Swedish c-TTO value set (Sun et al., 2022) / Swedish experience-based value set (Burström et al., 2020)]. The index is anchored at 1.00 (full health) and 0.00 (a state equivalent to dead), with negative values representing states considered worse than dead; the [Swedish c-TTO value set ranges from -0.31 to 1.00 / Swedish experience-based value set ranges from 0.243 to 0.976]. Higher index values indicate better health-related quality of life (better outcome). The accompanying EQ visual analogue scale ranges from 0 (worst imaginable health) to 100 (best imaginable health), with higher scores indicating better self-rated health.
Measured: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up
Health-related quality of life (Assessment of Quality of Life-8 Dimensions, AQoL-8D)
Health-related quality of life measured with the Assessment of Quality of Life-8 Dimensions (AQoL-8D), a 35-item instrument covering eight dimensions (independent living, happiness, mental health, coping, relationships, self-worth, pain, senses). Item responses are converted into a single utility score using the Australian scoring algorithm, on a scale anchored at 1.00 (full health) and 0.00 (dead); the algorithmic range is 0.09 to 1.00. Higher scores indicate better health-related quality of life (better outcome).
Measured: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up
Health care use and productivity costs (Trimbos/iMTA Questionnaire for Costs Associated with Psychiatric Illness, TiC-P)
Health care utilisation and productivity losses measured with the Trimbos/iMTA Questionnaire for Costs Associated with Psychiatric Illness (TiC-P). The TiC-P is not scored as a rating scale: reported numbers of health care contacts and days of absenteeism and reduced productivity are multiplied by Swedish unit costs to yield costs in SEK. The minimum is 0 SEK and there is no fixed maximum. Higher values indicate greater resource use and productivity loss (worse outcome).
Measured: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up
Illness-related shame (Chronic Illness-related Shame Scale, CISS)
Illness-related shame measured with the Chronic Illness-related Shame Scale (CISS), a 7-item unidimensional self-report scale. Each item is rated from 0 (never true) to 4 (always true) and items are summed. Total score ranges from 0 to 28. Higher scores indicate greater illness-related shame (worse outcome).
Measured: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up
Psychological flexibility and inflexibility (Multidimensional Psychological Flexibility Inventory, MPFI)
Items are rated on a 6-point scale from 1 (never true) to 6 (always true). Global psychological flexibility and global psychological inflexibility composite scores are each calculated as the mean of their constituent items, giving a score range of 1 to 6 for each composite. Higher psychological flexibility scores indicate greater flexibility (better outcome); higher psychological inflexibility scores indicate greater inflexibility (worse outcome).
Measured: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up
Self-compassion (Self-Compassion Scale-Short Form, SCS-SF)
Self-compassion measured with the Self-Compassion Scale-Short Form (SCS-SF), a 12-item self-report scale. Items are rated from 1 (almost never) to 5 (almost always); negatively worded items are reverse-scored and the total score is the mean of all items, ranging from 1 to 5. Higher scores indicate greater self-compassion (better outcome).
Measured: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up
Treatment credibility and expectancy (Credibility/Expectancy Questionnaire, CEQ)
Treatment credibility and outcome expectancy measured with the Credibility/Expectancy Questionnaire (CEQ), a 6-item self-report measure. The credibility subscale (items 1-3) is rated from 1 (not at all) to 9 (very much) and summed, giving a range of 3 to 27. The expectancy subscale (items 4-6) combines one item rated from 1 to 9 and two items rated from 0% to 100%; these items are standardised and summed, so the subscale has no fixed raw minimum and maximum. Higher scores on both subscales indicate greater perceived treatment credibility and more positive outcome expectancy.
Measured: Week 0 (only expectancy sub scale), Week 4 (both subscales)
System usability (System Usability Scale, SUS)
Perceived usability of the online intervention platform measured with the System Usability Scale (SUS), a 10-item self-report scale. Items are rated from 1 (strongly disagree) to 5 (strongly agree); item scores are converted (odd-numbered items: response minus 1; even-numbered items: 5 minus response), summed and multiplied by 2.5. Total score ranges from 0 to 100. Higher scores indicate better perceived usability (better outcome).
Measured: Week 8
Negative effects of treatment (Negative Effects Questionnaire, 20-item version, NEQ-20)
Negative effects of treatment measured with the 20-item version of the Negative Effects Questionnaire (NEQ-20). For each item, participants indicate whether the negative effect occurred and, if so, rate its impact from 0 (not at all) to 4 (extremely) and attribute it either to the treatment or to other circumstances. The total score is the sum of the 20 items, ranging from 0 to 80. Higher scores indicate more frequent and more severe negative effects (worse outcome).
Measured: Week 8
Global impression of change (Patient Global Impression of Change, PGIC)
Participants' overall impression of change since starting the intervention (Week 0), measured with a single global change item rated on a 7-point scale from 0 (very much worse) to 6 (very much improved)]. A higher score indicates greater perceived improvement (better outcome).
Measured: Week 4, Week 8, 3 months follow-up, 6 months follow-up
Awareness of Processes Post-Intervention Scale
Participants' awareness of the therapeutic processes targeted by the intervention, measured with the Awareness of Processes Post-Intervention Scale, a study-specific [N]-item self-report measure. Each item is rated from 1 (not at all true) to 5 (very much true) and items are summed, giving a total score range of 9 to 45. Higher scores indicate greater awareness of the targeted processes.
Measured: Week 8
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Sep 2026
- Study start15 Sep 2026
- Primary completion30 Sep 2027 (estimated)
- Study completion30 Sep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Disorders of Gut-brain InteractionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Örebro University, Sweden
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ines Trindade, Örebro University, Sweden
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07814196
- Sponsor's protocol ID
- iACTforDGBI_RCT
- Acronym
- iACTforDGBI
- Status last verified
- Oct 2026
- First submitted
- 2 Sep 2026
- Last updated
- 23 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy, and Cost-effectiveness of an Online ACT Intervention for Disorders of Gut-Brain Interaction (iACTforDGBI)
- ClinicalTrials.gov ID
- NCT07814196
- Acronym / sponsor ID
- iACTforDGBI / iACTforDGBI_RCT
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Örebro University, SwedenUniversity, hospital or other
- Study start
- 15 Sep 2026 (actual)
- Primary completion
- 30 Sep 2027 (estimated)
- Study completion
- 30 Sep 2027 (estimated)
- First posted
- 10 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Test of efficacy and cost-effectiveness of the iACTforDGBI intervention vs an active control group (DGBI School)
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| iACTforDGBI intervention | Experimental | Behavioral: iACTforDGBI interventionACT, mindfulness, and compassion-based online intervention |
| DGBI School | Active comparator | Other: DGBI SchoolEducation on DGBI |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age between 18 and 75 years
- Meeting clinical symptom levels for least one DGBI diagnosis (assessed with the Rome IV Diagnostic Questionnaire for Functional Gastrointestinal Disorders in Adults (Palsson et al., 2016))
- Stable medication for psychiatric symptoms including anxiety, depression and sleep problems for at least two months prior to intervention.
- Ability to read and write Swedish
- Have access to a device (like computer, tablet or smartphone with) with access to the internet and that can be used to attend video conferences and preview the intervention platform (i.e., have a microphone and speakers or headphones).
Key exclusion criteria (3 listed)
- Currently undergoing any form of psychological intervention.
- Increased risk of suicide (≥4 points on MADRS item 9).
- Ongoing or previously diagnosed severe psychiatric disorder, such as schizophrenia spectrum disorders or bipolar disorder.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| iACTforDGBI interventionOnline ACT, mindfulness, and compassion-based intervention, 8 sessions | Behavioural | iACTforDGBI intervention |
| DGBI SchoolEducation on DGBI, diet, and psychological factors | Other | DGBI School |
Primary outcome
Depressive symptoms (Patient Health Questionnaire-9, PHQ-9)
Time frame: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up
Depressive symptoms measured with the Patient Health Questionnaire-9 (PHQ-9), a 9-item self-report scale. Each item is rated from 0 (not at all) to 3 (nearly every day) and items are summed. Total score ranges from 0 to 27. Higher scores indicate more severe depressive symptoms (worse outcome).
Gastrointestinal symptoms (Gastrointestinal Symptom Rating Scale, GSRS)
Time frame: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up
Gastrointestinal symptom severity measured with the Gastrointestinal Symptom Rating Scale (GSRS), a 15-item self-report scale. Each item is rated on a 7-point Likert scale from 1 (no discomfort) to 7 (very severe discomfort), and items are summed. Total score ranges from 15 to 105. Higher scores indicate more severe gastrointestinal symptoms (worse outcome).
Anxiety symptoms (Generalized Anxiety Disorder 7-item scale, GAD-7)
Time frame: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up
Anxiety symptoms measured with the Generalized Anxiety Disorder 7-item scale (GAD-7). Each of the 7 items is rated from 0 (not at all) to 3 (nearly every day) and items are summed. Total score ranges from 0 to 21. Higher scores indicate more severe anxiety symptoms (worse outcome).
11 secondary outcomes
Health-related quality of life (EuroQol 5-Dimension 5-Level, EQ-5D-5L)
Time frame: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up
Health-related quality of life (Assessment of Quality of Life-8 Dimensions, AQoL-8D)
Time frame: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up
Health care use and productivity costs (Trimbos/iMTA Questionnaire for Costs Associated with Psychiatric Illness, TiC-P)
Time frame: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up
Illness-related shame (Chronic Illness-related Shame Scale, CISS)
Time frame: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up
Psychological flexibility and inflexibility (Multidimensional Psychological Flexibility Inventory, MPFI)
Time frame: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up
Self-compassion (Self-Compassion Scale-Short Form, SCS-SF)
Time frame: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up
Treatment credibility and expectancy (Credibility/Expectancy Questionnaire, CEQ)
Time frame: Week 0 (only expectancy sub scale), Week 4 (both subscales)
System usability (System Usability Scale, SUS)
Time frame: Week 8
Negative effects of treatment (Negative Effects Questionnaire, 20-item version, NEQ-20)
Time frame: Week 8
Global impression of change (Patient Global Impression of Change, PGIC)
Time frame: Week 4, Week 8, 3 months follow-up, 6 months follow-up
Awareness of Processes Post-Intervention Scale
Time frame: Week 8
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Oct 2026.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Disorders of Gut-brain Interaction
RecruitingPhase 2
Exploring Novel Therapeutic Approaches for Disorders of Gut-Liver-Brain Interaction-H1/H2
Functional Gastrointestinal Disorders
Recruiting
Development of a Noninvasive Metric to Measure Small Bowel Sensation - The Small Intestine Stress Test
Disorders of Gut Brain Interaction
Recruiting
Individualized TCM Pattern-Based Thread-Embedding Acupuncture Plus Auricular Acupressure for Chronic Insomnia
Insomnia, Nonorganic, Chronic Insomnia Disorder
Recruiting
Comprehensive Management Strategies for Gastroesophageal Reflux Disease: A Study of Multidimensional Interventions and Health Impacts
Disorders of Gut-brain Interaction, Lifestyle and Dietary Interventions
Recruiting
Neuroregulators for the Treatment of Diseases Associated With Esophageal-brain-gut Axis Communication Abnormalities.
Gut-Brain Disorders, GERD Without Erosive Esophagitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing iACTforDGBI intervention and DGBI School in people with Disorders of Gut-brain Interaction and Distress, Psychological, run by Örebro University, Sweden at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 23 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Depressive symptoms (Patient Health Questionnaire-9, PHQ-9) (time frame: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Oct 2026.